Status:
COMPLETED
The Role of Matrix Metalloproteinase 2 and 9 Enzymes in Developing Chronic Thromboembolic Pulmonary Hypertension
Lead Sponsor:
AHMET ZENGIN
Conditions:
Chronic Thromboembolic Pulmonary Hypertension
Eligibility:
All Genders
18+ years
Brief Summary
Chronic thromboembolic pulmonary hypertension is an occlusive disease in pulmonary artery.Matrix metalloproteinase enzymes play a substantial role of extracellular matrix remodeling. The clot formed i...
Detailed Description
Chronic thromboembolic pulmonary hypertension is an occlusive disease in pulmonary artery. Only 4% of patients with acute pulmonary embolism develop chronic thromboembolic pulmonary hypertension and a...
Eligibility Criteria
Inclusion
- Despite 3 months of anticoagulation therapy
- mean pulmonary arterial pressure \> 20 mmHg
- pulmonary vasculary resistance \> 3 wood
- pulmonary capillary wedge pressure \< 15 mmHg
- perfusion defect in ventilation perfusion scintigraphy
- pulmonary angiography or computed tomography angiography showing pulmonary artery occlusive lesions
Exclusion
- Patients undergoing pulmonary thromboendarterectomy concomitant coronary bypass, carotid endarterectomy, aortic valve, ascending aorta, mitral valve, tricuspid valve, pulmonary valve surgery
- Patients who have undergone surgical or percutaneous procedures due to atherosclerotic disease
Key Trial Info
Start Date :
July 1 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
May 4 2021
Estimated Enrollment :
48 Patients enrolled
Trial Details
Trial ID
NCT04773028
Start Date
July 1 2020
End Date
May 4 2021
Last Update
August 10 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Kartal Kosuyolu High Speciality Training and Research Hospital
Istanbul, Eyalet/Yerleşke, Turkey (Türkiye), 34800